Oncolytic virus in combination with immune checkpoint inhibitor for treating tumors
AssigneeJoint Biosciences (Sh) Ltd.
InventorsGuoqing Zhou, He Yang, Fan Zhang, Suhong Zhang
Life of this patent
Estimating the term…
Abstract
The present application relates to a medicine for treating tumors. A novel attenuated oncolytic virus strain is provided by means of a site-directed mutation of a wild-type virus matrix protein M of a vesicular stomatitis virus. On the basis of the attenuated oncolytic virus strain, an oncolytic virus vaccine is provided by inserting an exogenous gene into the attenuated strain. A medicine capable of treating multiple types of tumors is provided by the use of the oncolytic virus vaccine in combination with the immune checkpoint inhibitor.
Claims8
A pharmaceutical composition, comprising an attenuated oncolytic virus strain and an immune checkpoint inhibitor, wherein the attenuated oncolytic virus strain is a vesicular stomatitis virus (VSV) MuddSummer subtype strain with an engineered matrix protein M, an engineering of the engineered matrix protein M comprises knocking out of leucine-encoding bases at position 111 of an amino acid sequence of a wild-type matrix protein M, and the amino acid sequence of the wild-type matrix protein M is shown as SEQ ID NO:
- 2;
- wherein an amino acid sequence of the engineered matrix protein M of the attenuated oncolytic virus strain is any one selected from a group consisting of the following amino acid sequences:
- SEQ ID NO:
- 4, SEQ ID NO:
- 7, SEQ ID NO:
- 8, SEQ ID NO:
- 9, SEQ ID NO:
- 10, and SEQ ID NO:
- 11.
Dependencies are inferred from the claim text.